| Literature DB >> 30024384 |
Pierre Martin1,2, Claire Bladier3, Bette Meek4, Olivier Bruyere5, Eve Feinblatt3, Mathilde Touvier6, Laurence Watier7, David Makowski8.
Abstract
BACKGROUND: Transparency when documenting and assessing weight of evidence (WOE) has been an area of increasing focus for national and international health agencies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30024384 PMCID: PMC6108859 DOI: 10.1289/EHP3067
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Figure 1.Keywords combined to produce the Scopus and PubMed search query.
Ranking considerations for the prescriptive nature, relevance, and feasibility of WOE approaches for ANSES evaluations.
| Consideration | Rank | Ranking |
|---|---|---|
| Prescriptive nature | 1 | No explicit rules |
| 2 | Some methodological elements for assessment and weighting defined but insufficiently detailed for non-expert users | |
| 3 | Implementation rules are well defined for most aspects of the WOE assessment | |
| 4 | Implementation rules are defined in sufficient detail to permit application by non-expert users | |
| Relevance | 1 | The specificity of the methodology restricts its use to specialized aspects or applications of WOE assessment for which it was developed |
| 2 | The methodology can be applied for a limited range of aspects or applications in hazard assessment within ANSES | |
| 3 | The methodology is applicable to most aspects or applications of a broader range of assessments of hazard within ANSES | |
| 4 | The methodology is sufficiently generic to be applicable to most aspects of a broad range of assessments of hazard within ANSES | |
| Feasibility | 1 | Implementation of the method is resource intensive (complexity high) and requires considerable specialized expertise and/or material resources |
| 2 | Implementation of the method impacts moderately on resources (moderate complexity), requiring some specific training | |
| 3 | Implementation of the method impacts minimally on resources and does not require specialized training, expertise and/or material resources | |
| 4 | Implementation of the method not anticipated to impact significantly on timeframe and resources for assessment |
Figure 2.Flow diagram of the study selection process using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, Moher et al. 2009).
WOE Approaches identified in the literature.
| Name | Description | Category | SR included | Form of evaluation | PF stages (step of stage) | Reference |
|---|---|---|---|---|---|---|
| AMSTAR | Assessment of syntheses of observational and clinical studies through the scoring (1–4) of 11 aspects | Method | Yes | Scoring | 2 (2) | Kung et al. ( |
| Bayesian inference | Statistical analysis combining expert knowledge (described by a prior probability distribution) with data to estimate a quantity of interest and analyze uncertainty | Method | No | Quantitative | 3; | BioBayes Group ( |
| Bradford Hill | Qualitative consideration of causality (9 aspects) in epidemiological studies | Method | No | Qualitative | 2 (3); | ANSES ( |
| Decision tree | Tool based on a tree-like graph describing options for various decision points | Method | No | Qualitative or quantitative | 3 | ANSES ( |
| Epid-Tox | Grid based on a five-step process to evaluate the quality of epidemiological and toxicological studies, and their intersection, to establish causal inference | Method | No | Qualitative | 2 (2); | Adami et al. ( |
| FDA | Qualitative evaluation of individual studies in humans and of the total scientific evidence based on study type, quantity of evidence, relevance to the target population, replication of study results and overall consistency | Method | No | Qualitative | 2 (1); | FDA ( |
| GRADE | Assessment of methodological flaws within the component studies, the consistency of results across different studies, the generalizability of research results to the wider patient base, and the effectiveness of treatments | Method | Yes | Scoring | 1; | Akl et al. ( |
| Hope and Clarkson | Weighting and integration of information relating cause and effect to estimate the probability of an adverse outcome for an ecological assessment endpoint | Framework | No | Scoring | 1; | Hope and Clarkson ( |
| Hypothesis-based | Fully expert-dependent assessment for various hypotheses for hazard identification of chemical substances | Method | No | Qualitative | 3; | Bailey et al. ( |
| IARC | Assessment of the quality of individual studies based on “principles of good practice” without reporting templates. Four categories for classification of combined evidence on toxicology and epidemiology and three for mode of action. Expert dependent | Method | No | Qualitative | 2 (2); | IARC ( |
| ILSI | Set of qualitative criteria to assess evidence on allergens proposed by the International Life Sciences Institute (ILSI) Europe Food Allergy Task Force | Method | No | Rank ordering | 2 (2); | Van Bilsen et al. ( |
| INCa | Criteria to assess evidence on nutritional factors and their associated cancer risk | Method | No | Qualitative | 2 (3); | INCa ( |
| Klimisch | Scoring of the quality of individual toxicological studies based on limited indicators for reliability, relevance, and adequacy of data | Method | No | Scoring | 2 (2) | ECHA ( |
| Meta-analysis | Statistical analysis of data collected in separate but similar studies, leading to the estimation of the magnitude of an effect and associated confidence interval | Method | Yes | Quantitative | 2 (3) | Chalmers et al. ( |
| Modified Bradford Hill | Comparative analysis for alternative mode of action hypotheses based on rank ordering of a subset of Bradford Hill considerations, taking into account epidemiological, toxicological and mechanistic data | Method | No | Rank ordering | 3; | Boobis et al. ( |
| Multi-criteria analysis | Expert-based quantitative judgment of quality of studies and their integration, including sensitivity and uncertainty analysis | Method | No | Quantitative or scoring | 2 (2); | Hristozov et al. ( |
| Navigation Guide | Synthesis of results for the reproductive and developmental hazards of chemical agents in the research context through 4 steps focused principally on systematic review | Method | Yes | Scoring | 2 (1); | Viswanathan et al. ( |
| NRC | Principal focus on systematic review | Framework | Yes | Scoring | 1; 2 (1); | |
| OHAT | Detailed documentation of components for all stages | Framework | Yes | Scoring | 1; 2 (1); 2 (2); 2 (3); | Howard et al. ( |
| SCENIHR | Considerations to address individual studies in 3 categories for quality and relevance and 3 categories for coherence between studies of similar type with weighting of lines of evidence by utility/coherence | Framework | No | Scoring | 2 (1); 2 (2); 2 (3); | SCENIHR ( |
| SR-Cochrane | Handbook for Systematic Reviews of Interventions. Planning: PICO for question formulation, detailed specification of search strategy, documentation of bias in study selection and presentation of results, their applicability, quality (in 4 categories) and outcome (EPICOT) | Method | Yes | Qualitative | 1; | Bilotta et al. ( |
| SR-EFSA | Detailed planning, process and documentation of systematic review, including PICO, PECO, PIT and PO and selection of studies (modification of SR-Cochrane) | Method | Yes | Qualitative | 1; | EFSA ( |
| WCRF/AICR | Classification regarding nutrition and cancer risk relationships. Evaluation of individual studies (epidemiological and mechanistic) based on good practice, meta-analysis of epidemiological studies identified through systematic review, and consideration of mechanistic data in relation to the biological plausibility of human data. Classification of WOE for each nutritional factor in 5 classes | Method | Yes | Qualitative | 2 (2); 2 (3); | WCRF/AICR ( |
| Weighted Bradford Hill | Estimation of the probability of causality in epidemiological studies through expert assessment of the extent of supporting data for each of 9 weighted Bradford Hill considerations | Method | No | Quantitative | 2 (3); | Swaen and van Amelsvoort ( |
Note: AMSTAR, Assessing the Methodological Quality of Systematic Reviews; EFSA, European Food Safety Authority; FDA, U.S. Food and Drug Administration; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IARC, International Agency for Research on Cancer; ILSI, International Life Sciences Institute; INCa, Institut National du Cancer/French National Cancer Institute; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; PF, Practical Framework; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; SR, Systematic Review; WCRF/AICR, World Cancer Research Fund and American Institute for Cancer Research; WHO, World Health Organization.
Semiquantitative refers to approaches that include scoring and rank ordering of various components, without quantitation.
Areas of application for the 24 WOE approaches screened by the literature review.
| Approaches | Safety at work | Food microbiology | Food chemistry | Nutrition | Animal feed and health | Environmental health | Crop protection products, biocides and fertilizers | Medical | Ecology-environment |
|---|---|---|---|---|---|---|---|---|---|
| AMSTAR | X | ||||||||
| Bayesian inference | X | X | |||||||
| Bradford Hill | X | X | X | X | |||||
| Decision tree | X | X | X | X | |||||
| Epid-Tox | X | X | X | ||||||
| FDA | X | X | |||||||
| GRADE | X | X | X | ||||||
| Hope and Clarkson | X | ||||||||
| Hypothesis based | X | ||||||||
| IARC | X | X | X | X | X | X | |||
| ILSI | X | ||||||||
| INCa | X | X | |||||||
| Klimisch | X | X | X | ||||||
| Meta-analysis | X | X | X | ||||||
| Modified Bradford Hill | X | X | X | X | |||||
| Multi-criteria analysis | X | X | X | ||||||
| Navigation Guide | X | ||||||||
| NRC | X | X | |||||||
| OHAT | X | ||||||||
| SCENIHR | X | ||||||||
| SR-Cochrane | X | ||||||||
| SR-EFSA | X | X | X | X | |||||
| WCRF/AICR | X | X | |||||||
| Weighted Bradford Hill | X |
Note: AMSTAR, Assessing the Methodological Quality of Systematic Reviews; EFSA, European Food Safety Authority; FDA, U.S. Food and Drug Administration; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IARC, International Agency for Research on Cancer; ILSI, International Life Sciences Institute; INCa, Institut National du Cancer/French National Cancer Institute; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; PF, Practical Framework; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; SR, Systematic Review; WCRF/AICR, World Cancer Research Fund and American Institute for Cancer Research.
Descriptions of approaches and associated references are included in Table 2.
Figure 3.Stages addressed in the five WOE frameworks identified in the literature.
Figure 4.Practical framework for weight of evidence assessment.
Ranking of the methods for planning the assessment.
| Approach | Prescriptive nature | Relevance | Feasibility |
|---|---|---|---|
| GRADE | 4 | 3 | 3 |
| Hope and Clarkson | 2 | 2 | 3 |
| NRC | 4 | 3 | 3 |
| OHAT | 4 | 3 | 3 |
| SR-Cochrane | 4 | 3 | 3 |
| SR-EFSA | 4 | 3 | 3 |
Note: GRADE, Grading of Recommendations Assessment, Development and Evaluation; EFSA, European Food Safety Authority; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; SR, Systematic Review.
The rankings were assigned to the methods by the authors collectively and reflect relative consideration of each of the three aspects defined and outlined in the Methods and Table 1: the extent of prescriptive nature contributing to transparency and reproducibility, relevance to be broadly applied within ANSES, and ease of implementation in terms of time and material/human resources (feasibility). Each aspect is ranked from 1 (i.e., the least) to 4 (i.e., the most).
Ranking of the methods for establishing lines of evidence.
| Approach | Identifying and selecting studies | Assessing the quality of the studies | Analyzing a set of studies of similar type | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PN | REL | FEA | PN | REL | FEA | PN | REL | FEA | |
| AMSTAR | NA | NA | NA | 4 | 3 | 4 | NA | NA | NA |
| Bradford Hill | NA | NA | NA | NA | NA | NA | 2 | 4 | 4 |
| Epid-Tox | NA | NA | NA | 2 | 4 | 4 | 2 | 4 | 3 |
| FDA | NA | NA | NA | 3 | 4 | 4 | 2 | 3 | 3 |
| GRADE | NA | NA | NA | 4 | 3 | 3 | 2 | 3 | 4 |
| Hope and Clarkson | NA | NA | NA | 2 | 3 | 3 | 2 | 3 | 3 |
| IARC | NA | NA | NA | 2 | 4 | 4 | 2 | 3 | 4 |
| ILSI | NA | NA | NA | 2 | 3 | 3 | 3 | 2 | 3 |
| INCa | 3 | 2 | 4 | 3 | 2 | 4 | NA | NA | NA |
| Klimisch | NA | NA | NA | 2 | 3 | 4 | NA | NA | NA |
| Meta-analysis | NA | NA | NA | NA | NA | NA | 4 | 4 | 1 |
| Modified Bradford Hill | NA | NA | NA | NA | NA | NA | 3 | 3 | 3 |
| Multi-criteria analysis | NA | NA | NA | 2 | 4 | 3 | 2 | 4 | 3 |
| Navigation Guide | 1 | 3 | 2 | 1 | 3 | 4 | 1 | 3 | 3 |
| OHAT | 3 | 3 | 2 | 3 | 3 | 4 | 2 | 3 | 3 |
| SR-Cochrane | 3 | 3 | 2 | 2 | 4 | 4 | NA | NA | NA |
| SR-EFSA | 3 | 3 | 2 | NA | NA | NA | NA | NA | NA |
| SCENIHR | NA | NA | NA | 2 | 3 | 4 | 1 | 3 | 4 |
| WCRF/AICR | NA | NA | NA | 2 | 4 | 4 | 4 | 4 | 2 |
| Weighted Bradford Hill | NA | NA | NA | NA | NA | NA | 3 | 3 | 3 |
Note: AMSTAR, Assessing the Methodological Quality of Systematic Reviews; EFSA, European Food Safety Authority; FDA, U.S. Food and Drug Administration; FEA, Feasibility; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IARC, International Agency for Research on Cancer; ILSI, International Life Sciences Institute; INCa, Institut National du Cancer/French National Cancer Institute; NA, Not applicable because the corresponding step was not addressed by the approach; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; PF, Practical Framework; PN, Prescriptive nature; REL, Relevance; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; SR, Systematic Review; WCRF/AICR, World Cancer Research Fund and American Institute for Cancer Research.
The rankings were assigned to the methods by the authors collectively and reflect relative consideration of each of the three aspects defined and outlined in the Methods and Table 1: the extent of prescriptive nature contributing to transparency and reproducibility, relevance to be broadly applied within ANSES, and ease of implementation in terms of time and material/human resources (feasibility). Each aspect is ranked from 1 (i.e., the least) to 4 (i.e., the most).
Ranking of the methods for integrating lines of evidence.
| Approach | Prescriptive nature | Relevance | Feasibility |
|---|---|---|---|
| Bayesian inference | 3 | 4 | 2 |
| Bradford Hill | 2 | 4 | 4 |
| Decision tree | 1 | 3 | 3 |
| Epid-Tox | 2 | 4 | 3 |
| Hope and Clarkson | 3 | 3 | 3 |
| Hypothesis based | 2 | 3 | 3 |
| IARC | 3 | 3 | 4 |
| INCa | 3 | 3 | 4 |
| Multi-criteria analysis | 2 | 4 | 3 |
| Modified Bradford Hill | 3 | 3 | 3 |
| Navigation Guide | 1 | 3 | 3 |
| OHAT | 3 | 3 | 4 |
| SCENIHR | 2 | 3 | 4 |
| WCRF/AICR | 3 | 3 | 4 |
| Weighted Bradford Hill | 3 | 4 | 4 |
Note: IARC, International Agency for Research on Cancer; INCa, Institut National du Cancer/French National Cancer Institute; OHAT, Office of Health Assessment and Translation; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; WCRF/AICR, World Cancer Research Fund and American Institute for Cancer Research.
The rankings were assigned to the methods by the authors collectively and reflect relative consideration of each of the three aspects defined and outlined in the Methods and Table 1: the extent of prescriptive nature contributing to transparency and reproducibility, relevance to be broadly applied within ANSES, and ease of implementation in terms of time and material/human resources (feasibility). Each aspect is ranked from 1 (i.e., the least) to 4 (i.e., the most).
Example of weight of evidence classifications.
| Method/framework | Reference | Number of Classes | Class title |
|---|---|---|---|
| Bayesian Inference | Schleier et al. ( | NA | NA |
| Epid-Tox | Adami et al. ( | 4 | Likely, Uncertain, Uncertain but plausible, Unlikely (Used to qualify the causal relationship between the environmental factor and the disease condition) |
| GRADE | Andrews et al. ( | 4 | Strong Against, Weak Against, Weak For, Strong For |
| Hope and Clarkson | Hope and Clarkson ( | 5 | Weak, Not indicated, Not indicated, Not indicated, Strong |
| IARC | IARC ( | 5 | Group 1: The agent is carcinogenic to humans Group 2A: The agent is probably carcinogenic to humans Group 2B: The agent is possibly carcinogenic to humans Group 3: The agent is not classifiable as to its carcinogenicity to humans Group 4: The agent is probably not carcinogenic to humans |
| Modified Bradford Hill | Meek et al. ( | 3 | Weak, Moderate, Strong |
| Multi-criteria analysis | Linkov et al. ( | 6 | Do nothing, Institutional control, Clay capping, Mechanical dredging, Hydraulic dredging, Hot spot dredging |
| NRC | NRC ( | 5 | Carcinogenic to humans, Likely to be carcinogenic to humans, Suggestive evidence of carcinogenic potential, Inadequate information to assess carcinogenic potential, Not likely to be carcinogenic to humans |
| OHAT | OHAT ( | 5 | (1) Known to be a hazard to humans, (2) Presumed to be a hazard to humans, (3) Suspected to be a hazard to humans, (4) Not classifiable as a hazard to humans, or (5) Not identified as a hazard to humans |
| SR–Cochrane | Higgins and Green ( | 4 | Very low, Low, Moderate, Strong |
| SR-EFSA | EFSA ( | NA | NA |
| SCENIHR | SCENIHR ( | 5 | Weighting not possible, Uncertain, Weak, Moderate, Strong |
| WCRF/AICR | WCRF/AICR ( | 5 | Convincing/Probable/Limited - suggestive/Limited - no conclusion/Substantial effect on risk unlikely |
Note: EFSA, European Food Safety Authority; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NA, Not applicable because the corresponding step was not addressed by the approach; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; SR, Systematic Review; WCRF/AICR, World Cancer Research Fund and American Institute for Cancer Research.
Ranking of the methods for expressing weight of evidence conclusions.
| Approach | Prescriptive nature | Relevance | Feasibility |
|---|---|---|---|
| Bayesian inference | 3 | 4 | 2 |
| Epid-Tox | 3 | 4 | 4 |
| GRADE | 3 | 4 | 4 |
| Hope and Clarkson | 3 | 3 | 3 |
| IARC | 3 | 4 | 4 |
| Modified Bradford Hill | 3 | 2 | 3 |
| Multi-criteria analysis | 3 | 3 | 3 |
| NRC | 3 | 4 | 3 |
| OHAT | 3 | 4 | 4 |
| SR-Cochrane | 4 | 4 | 3 |
| SR-EFSA | 4 | 4 | 3 |
| SCENIHR | 3 | 4 | 3 |
| WCRF/AICR | 4 | 3 | 4 |
Note: EFSA, European Food Safety Authority; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IARC, International Agency for Research on Cancer; NRC, U.S. National Research Council; OHAT, Office of Health Assessment and Translation; SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks; SR, Systematic Review.
The rankings were assigned to the methods by the authors collectively and reflect relative consideration of each of the three aspects defined and outlined in the Methods and Table 1: the extent of prescriptive nature contributing to transparency and reproducibility, relevance to be broadly applied within ANSES, and ease of implementation in terms of time and material/human resources (feasibility). Each aspect is ranked from 1 (i.e., the least) to 4 (i.e., the most).